Androgen receptor mutations in prostate cancer

Mount Sinai Journal of Medicine

Volumn 63, Issue 5-6, 1996, Pages 403-412

  Barrack, Evelyn R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

CELL CULTURE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; METABOLISM; MUTATION; PATHOLOGY; PROSTATE TUMOR; REVIEW;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MUTATION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

EID: 0030265868     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45:8-30.
2. Ross RK, Paganini-Hill A, Henderson BE. The etiology of prostate cancer: What does the epidemiology suggest? Prostate 1983; 4:333-344.
3. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocrine Rev 1987; 8:338-362.
4. Luke MC, Coffey DS. The male sex accessory tissues. Structure, androgen action, and physiology. In: Knobil E, Neill JD, editors. The physiology of reproduction, 2nd ed. New York: Raven Press, 1994: 1435-1487.
5. Barrack ER, Tindall DJ. A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. Prog Clin Biol Res 1987; 239:155-187.
6. Sadi MV, Barrack ER. Androgen receptors in prostate cancer. pp. 239-265 In: Pretlow II TG, Pretlow TP, editors. Biochemical and molecular aspects of selected cancers, vol. 2. New York: Academic Press, 1994: 239-265.
7. Catalona WJ, Scott WW. Carcinoma of the prostate. In: Walsh PC, Gittes RF, Perlmutter AD, Stamey TA, editors. Campbell's Urology, 5th ed. Philadelphia: WB Saunders, 1986: 1463-1534.
8. Wilding G. The importance of steroid hormones in prostate cancer. Cancer Surv 1992; 14:113-130.
9. Scott WW, Menon M, Walsh PC. Hormonal therapy of prostatic cancer. Cancer 1980; 45:1929-1936.
10. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991; 48:189-193.
11. Ruizeveld de Winter JA, Janssen JA, Sleddens HMEB, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994; 144:735-746.
12. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54:5474-5478.
13. Denner LA, Weigel NL, Maxwell BL, et al. Regulation of progesterone receptor-mediated transcription by phosphorylation. Science 1990; 250:1740-1743.
14. Power RF, Mani SK, Codina J, et al. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 1991; 254:1636-1639.
15. Aronica SM, Katzenellenbogen BS. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 1993; 7:743-752.
16. Ignar-Trowhridge DM, Teng CT, Ross KA, et al. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 1993; 7:992-998.
17. Lubahn DB, Joseph DR, Sar M, et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 1988; 2:1265-1275.
18. Chang C, Kokontis J, Liao S. Structural analysis of cDNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA 1988; 85:7211-7215.
19. Simental JA, Sar M, Lane MV, et al. Transcriptional activation and nuclear targeting signals of the human androgen receptor J Biol Chem 1991; 266:510-518.
20. Jenster G, van der Korput HAGM, van Vroonhoven C, et al. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 1991; 5:1396-1404.
21. Fuqua SAW, Fitzgerald SD, Chamness GC, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991; 51:105-109.
22. Wang Y, Miksicek RJ. Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol 1991; 5:1707-1715.
23. Castles CG, Fuqua SAW, Klotz DM, Hill SM. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 1993; 53:5934-5939.
24. Culig Z, Klocker H, Eberle J, et al. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993; 22:11-22.
25. Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocrine Rev 1995; 16:272-321.
26. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173:534-540.
27. Veldscholte J, Berrevoets CA, Brinkmann AO, et al. Anti-androgens and the mutated androgen receptor of LN-CaP cells: differential effects on binding affinity, heat shock protein interactions, and transcriptional activation. Biochemistry 1992; 31:2393-2399.
28. Newmark JR, Hardy DO, Tonb DC, et al. Androgen receptor gene mutations in prostate cancer. Proc Natl Acad Sci USA 1992; 89:6319-6323.
29. Charest NJ, Zhou Z-X, Lubahn DB, et al. A frameshift mutation destabilizes androgen receptor messenger RNA in the Tfm mouse. Mol Endocrinol 1991; 5:573-581.
30. Nastiuk KL, Clayton DF. Seasonal and tissue-specific regulation of canary androgen receptor messenger ribonucleic acid. Endocrinology 1994; 134:640-649.
31. Schoenberg MP, Tonb DC, Brown TR, Barrack ER. Functional analysis of an androgen receptor gene mutation in localized human prostate cancer. Abstract presented at the 7th Annual Meeting of the Society for Basic Urologic Research; May 14-15, 1993; San Antonio, Texas.
32. Vegeto E, Shahbaz MM, Wen DX, et al. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993; 7:1244-1255.
33. Ince BA, Montano MM, Katzenellenbogen BS. Activation of transcriptionally inactive human estrogen receptors by cyclic adenosine 3′,5′-monophosphate and ligands including antiestrogens. Mol Endocrinol 1994; 8:1397-1406.
34. Tzukerman MT, Esty A, Santiso-Mere D, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994; 8:21-30.
35. Stober J, Culig Z, Gast A, et al. Ligand specific modulation of activity of mutant androgen receptors from human prostate cancer: a model for investigating hormone-receptor interactions. Abstract presented at AACR Special Conference on Basic and Clinical Aspects of Prostate Cancer; December 8-12, 1994; Palm Springs, CA.
36. Suzuki H, Sato N, Watabe Y, et al. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993; 46:759-765.
37. Batch JA, Williams DM, Davies HR, et al. Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome. Hum Mol Genet 1992; 1:497-503.
38. Gerber H-P, Seipel K, Georgiev O, et al. Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science 1994; 263:808-811.
39. Emili A, Greenblatt J, Ingles CJ. Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. Mol Cell Biol 1994; 14:1582-1593.
40. Perutz MF, Johnson T, Suzuki M, Finch JT. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA 1994; 91:5355-5358.
41. Edwards A, Hammond HA, Jin L, et al. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992; 12:241-253.
42. La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352:77-79.
43. Macke JP, Hu N, Hu S, et al. Sequence variation in the androgen receptor gene is not a common determinant of male sexual orientation. Am J Hum Genet 1993; 53: 844-852.
44. Sleddens HFBM, Oostra BA, Brinkmann AO, Trapman J. Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet 1993; 2:493.
45. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22:3181-3186.
46. Mhatre AN, Trifiro MA, Kaufman M, et al. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nature Genet 1993; 5:184-188.
47. Sobue G, Doyu M, Morishima T, et al. Aberrant androgen action and increased size of tandem CAG repeat in androgen receptor gene in X-linked recessive bulbospinal neuronopathy. J Neurol Sci 1994; 121:167-171.
48. Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 1994; 54:5059-5063.
49. Martin JB. Molecular genetics of neurological diseases. Science 1993; 262:674-676.
50. 24→18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 1994; 198:74-80.
51. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11:1566-1572.
52. Sartor O, Cooper M, Weinberger M, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone refractory" prostate cancer. J Natl Cancer Inst 1994; 86:222-227.
53. Bussemakers MJG, Bova GS, Schoenberg MP, et al. Microsatellite instability in human prostate cancer (abstract 967). J Urol 1994; 151:469A.
54. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7:1541-1550.
55. Gaddipati JP, McLeod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancer. Cancer Res 1994; 54:2861-2864.
56. Taplin M-E, Bubley G, Balk S. Molecular analysis of the androgen receptor in androgen independent prostate cancer. Presented at Basic and Clinical Aspects of Prostate Cancer, An AACR Special Conference; December 8-12, 1994; Palm Springs, CA.
57. Ris-Stalpers C, Verleun-Mooijman MCT, Trapman J, Brinkmann AO. Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity. Biochem Biophys Res Commun 1993; 196:173-180.
58. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990; 143:742-746.
59. Takahashi H, Furusato M, Allsbrook WC, Boyd J. Inactivating mutations of the androgen receptor gene in latent prostatic carcinomas (abstract 1621). Proc Am Assoc Cancer Res 1994; 35:271.
60. Hakimi JM, Schoenberg MP, Barrack ER. Androgen receptor variants as a potential risk factor for aggressive prostate cancer (abstract 216). J Urol 1995; 153:282A.